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Polysulphated polysaccharide rugs (PPDs) owe their diverse range of biological activities to their structural 
resemblance to the naturally occurring sulphated glycosaminoglycans (S-GAGs), such as dermatan sulphate, 
heparin and heparin sulphate. S-GAGs in the form of complexes with proteins (proteoglycans) are ubiquitous 
in mammalian tissues. These proteoglycan complexes occupy sites on cell surfaces where they modulate 
growth factors and chemokine activities. They bind to blood proteins and are part of the extracellular matrix 
where they regulate cell division, differentiation, macromolecule synthesis, assembly and turnover. One of 
the most exten§ively studied PPDs is pentosan polysulphate (PPS), a semi-synthetic product, more highly 
sulphated than heparin but with a much smaller molecular weight (~ 5700 Da). Because of its high charge 
density, PPS is able to displace bioactive proteins from many of their heparin and heparan binding sites. In 
addition, PPS exhibits tereospecific interactions with cell receptors and proteins not usually occupied by 
endogenous S-GAGs. 
Osteoarthritis (OA) is a multifactorial disorder which is characterised by extensive pathological changes 
in joint connective tissues, including cartilage, subchondral bone, synovial lining and capsule and within 
the synovial fluid (SF) itself. All of these tissues are rich in S-GAGs but in OA their prescribed functions 
and structural roles may be modified by inflammatory mediators or proteinases implicated in the 
pathogenesis of this disease. PPS by virtue of its molecular size and charge readily targets OA joint tissues 
where it displays multiple pharmacological actions which may be of benefit in restoring tissue homeostasis. 
In articular cartilage matrix biosynthesis (proteoglycans and hyaluronan) and chondrocyte proliferation 
(DNA) are upregulated by PPS, while some proteolytic activities (elastase, cathepsin b, metalloproteinases) 
are inhibited. Although inflammatory cell infiltration into synovium and SF in OA joints are not reduced 
by PPS, production by these cells of certain cytokines, proteinases and free radicals, is modulated [(eg. TNF-a 
reduced, IL-6 increased, nitric oxide (NO) reduced, superoxide dismutase (SOD) increased)]. Moreover, 
synoviocyte proliferation and biosynthesis ofhyaluronan are increased and the rheological abnormalities 
of OA-SF may be corrected accordingly. Intraosseous engorgement of the subchondral bone due to 
accumulation f fibrin and lipid in capillary endothel ium is a common feature of OA joints. PPS stimulates 
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tissue plasminogen activator (tPA) expression by endothelial cells while levels of its inhibitor (PAI) are 
decreased by the drug. Apart from its fibrinolytic activity, PPS mobilise lipids through release of bound 
lipases, as well as SOD and platelet factor 4, from endothelial nd hepatic ells. Recent findings of decreased 
levels of osteocalcin in SF of PPS-treated OA patients uggests that osteoclast  activity may also be 
modulated by this drug, however this preliminary finding has yet to be confirmed. 
While disease modification in OA could be considered as the "Holy Grail" of rheumatology, many have 
questioned its reality. However, mounting data on the pharmacology of PPS suggests that we may shortly 
be in a position to challenge this dogma. 
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Disease modifying properties of sodium pentosan polysulphate (NaPPS) and insulin-like growth factor-1 
(IGF-1) in osteoarthritis (OA) were assessed in the Pond-Nuki canine cruciate deficiency model of OA. There 
were 5 groups of animals: N= unoperated controls; C = operated controls; PPS = intramuscular PPS, 2 mg/kg 
weeks 4 through 6; IGF-1 = intraarticular IGF-1 1 #g three times each week from week 4 through 6; 
PPS/ IGF-1  = both PPS and IGF-1 in the above regimen. At 6 weeks, femoral condylar cartilage was assessed 
for anatomy, histology (Mankin score) and biochemistry. 
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Results 
Anatomy: PPS/ IGF-1  approximated N.
Histology: PPS and PPS/ IGF-1  less severe than OA. 
Biochemistry: PPS had less enzyme than OA for active neutral metalloproteinase. PPS/ IGF-1  had near N 
active and total neutral metalloproteinase, tissue inhibitor of metalloproteinase, total 
collagenase, uronate and hydroxyproline. 
Conclusion 
NaPPS and particularly NaPPS combined with IGF-1 was able to interfere with the progression of OA in 
an animal model. It is hypothesized that proteinase activity was blocked by the NaPPS. The absence of 
effective proteinase activity is hypothesized to permit growth factor stimulation. 
Since it appears that a combination ofagents will be needed to effectively modify cartilage metabolism, this 
approach to therapeutics appears to be a rationale approach to disease modification i  OA. 
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Introduct ion 
In an established rabbit model of inflammatory arthritis induced by intra-articular injection of a hyaluronan 
poly-D-lysine complex (PC), calcium pentosan polysulphate (CaPPS, 10 mg/kg orally) demonstrated a 
